Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
Loncastuximab and Roflumilast Added to R-CHOP (Lo-RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Target Recruit Count
- 10
- Registration Number
- NCT06977711
- Locations
- 🇺🇸
University Hospital System, San Antonio, Texas, United States
🇺🇸University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center, San Antonio, Texas, United States
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
- Conditions
- LymphomaLymphoma, B-Cell
- Interventions
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Jennifer Amengual
- Target Recruit Count
- 30
- Registration Number
- NCT06954805
- Locations
- 🇺🇸
Stanford Medical Center, Stanford, California, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
- Conditions
- CNS Embryonal TumorCNS, MedulloblastomaAtypical Teratoid Rhabdoid TumorMedulloblastoma, ChildhoodMedulloblastoma, Group 3Medulloblastoma, Group 4PineoblastomaEmbryonal Tumor With Abundant Neuropil and True RosettesEpendymoblastomaMedulloepithelioma
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- C17 Council
- Target Recruit Count
- 15
- Registration Number
- NCT06942039
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeLymphoblastic Lymphoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Lumbar PunctureProcedure: Positron Emission Tomography
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 53
- Registration Number
- NCT06918431
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope at Irvine Lennar, Irvine, California, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4)
- Conditions
- Follicular Lymphoma
- Interventions
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 400
- Registration Number
- NCT06911502
- Locations
- 🇺🇸
Local Institution - 0214, Tampa, Florida, United States
🇵🇱Local Institution - 0189, Łódź, Łódzkie, Poland
🇺🇸Local Institution - 0008, Jacksonville, Florida, United States
Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
- Conditions
- CIC-Rearranged SarcomaSarcoma With BCOR Genetic AlterationsMetastatic Ewing SarcomaMetastatic High Grade SarcomaMetastatic Undifferentiated Round Cell SarcomaRound Cell Sarcoma With EWSR1-non-ETS FusionMetastatic Undifferentiated Sarcoma, Not Otherwise Specified
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Echocardiography TestOther: Fludeoxyglucose F-18Procedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Surgical Procedure
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 437
- Registration Number
- NCT06820957
UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors
- Conditions
- Pediatric Solid Tumor
- Interventions
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 39
- Registration Number
- NCT06760117
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
- Conditions
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeT Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow CollectionProcedure: Computed TomographyProcedure: Positron Emission Tomography
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 30
- Registration Number
- NCT06738368
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Conditions
- Refractory Solid TumorsRelapsed Solid TumorsRelapsed NeuroblastomaRefractory NeuroblastomaRelapsed RhabdomyosarcomaRefractory Rhabdomyosarcoma
- Interventions
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Theodore Laetsch
- Target Recruit Count
- 59
- Registration Number
- NCT06721689
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1046
- Registration Number
- NCT06717347
- Locations
- 🇺🇸
Cancer Blood and Specialty Clinic ( Site 0109), Los Alamitos, California, United States
🇺🇸Cancer Care Specialists of Illinois ( Site 0152), O'Fallon, Illinois, United States
🇺🇸Fort Wayne Medical Oncology and Hematology ( Site 0149), Fort Wayne, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.